CERo Therapeutics (CERO) presented preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific ...
JonesResearch upgraded CervoMed (CRVO) to Buy from Hold with a $15 price target arguing that the company’s latest data from the open label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback